Investigator Sponsored Research (ISR) supports independent investigators and research organizations studying products, diseases, conditions, and technologies to advance medical and scientific knowledge.
Japan ISR removed mirabegron from eligible clinical products and removed mirabegron, enzalutamide, and ipragliflozin from material supply. Research priorities also changed across the remaining products, including removal of zolbetuximab combination/resistance topics and a new exclusion of enfortumab vedotin studies outside urothelial cancer.
Funder: Astellas
Due Dates: November 30, 2026 (Japan clinical research) | Rolling (Japan product-material requests)
Funding Amounts: Japan: generally funding for clinical research; product materials for nonclinical research
Summary: Supports independent research advancing knowledge of products, diseases, medical conditions, and technologies.
Key Information: Requests must be unsolicited; independent sponsors retain responsibility for research design, conduct, analysis, and dissemination.
Astellas’s Investigator Sponsored Research (ISR) program supports independent, innovative studies that advance medical and scientific knowledge. Research may address a product, disease state, medical condition, or advancing technology. Current areas of interest identify compounds with open programs and guide submissions, but alignment does not guarantee support.
In Japan, ISR supports investigator-led clinical and nonclinical studies using Astellas medicines to establish better treatments. Clinical research generally must follow indications, dosage, and administration approved in Japan. Nonclinical proposals may explore new disease applications, with priority given to diseases lacking treatments or inadequately served by existing medicines. Japan-specific eligibility, products, and submission arrangements are outlined below.